Glaukos (NYSE:GKOS) & Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Head-To-Head Review

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Institutional & Insider Ownership

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 5.8% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Fresenius Medical Care AG & Co. KGaA has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Fresenius Medical Care AG & Co. KGaA and Glaukos”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$22.20 billion	0.54	$1.11 billion	$1.90	11.31
Glaukos	$507.44 million	16.44	-$187.69 million	($3.28)	-43.31

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fresenius Medical Care AG & Co. KGaA and Glaukos, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	4	5	0	0	1.56
Glaukos	1	1	11	1	2.86

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $28.00, suggesting a potential upside of 30.27%. Glaukos has a consensus target price of $144.42, suggesting a potential upside of 1.67%. Given Fresenius Medical Care AG & Co. KGaA’s higher possible upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Glaukos.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Glaukos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%
Glaukos	-34.34%	-6.92%	-5.25%

Summary

Fresenius Medical Care AG & Co. KGaA beats Glaukos on 8 of the 15 factors compared between the two stocks.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.